Clinical trials: BRONCHIAL ASTHMA
Asthma
A Study of RO5036505 in Patients With Moderate to Severe Asthma
This randomized, double-blind, placebo-controlled study will evaluate the efficacy, safety and tolerability of RO5036505 in patients with inadequately controlled moderate to severe asthma.
- Trial name
- NCT00967590
- Testing
- RO5036505
- Where
- 16 sites in United States, United Kingdom
- Sponsor
- Hoffmann-La Roche
Asthma
Integrated Digitally Enhanced Care for Long-term Conditions- Asthma
Asthma is a common lung condition that causes long term breathing difficulties. There is currently no cure for asthma but the use of simple inhaler treatments can keep the symptoms under control.
- Trial name
- IDEAL (NCT03511482)
- Testing
- myAsthma Application, Lloyds Pharmacy Online Doctor
- Where
- United Kingdom
- Sponsor
- my mhealth Ltd
Asthma
A Phase 3, Multicenter, Open-label Continuation Study in Moderate to Severe Asthmatic Subjects Who Completed FlutiForm HFA pMDI Study SKY2028-3-005
The objective of this study is to assess the long-term safety and efficacy of FlutiForm HFA pMDI 250/10 mcg bid in adolescents and adults with moderate to severe asthma who have completed the study SKY2028-3-005.
- Trial name
- NCT00747318
- Testing
- SKP FlutiForm HFA pMDI
- Where
- 39 sites in United States, Mexico and 3 more
- Volunteers
- 280 people
- Sponsor
- SkyePharma AG
Uncontrolled and Persistent Asthma
Study to Investigate Relative Bioavailability of up to Five Different Formulations of AZD5069
Study to investigate relative bioavailability of up to five different formulations of AZD5069
- Trial name
- NCT01989520
- Testing
- Phase IIb formulation, Putative phase III formulation, Slow dissolution variant 1
- Where
- United Kingdom
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Asthma
A Non- Inferiority Comparative Study Between Seretide® and Salmeterol/Fluticasone Eurofarma in Patients with Asthma
The primary objective will be to compare the formulations regarding their impact on the pulmonary function of persistent asthma patients and the secondary objective will be the clinical control of the disease's symptoms.
- Trial name
- CAINAS SF (NCT01202097)
- Testing
- Salmeterol/Fluticasone, Seretide
- Where
- 6 sites in Brazil
- Volunteers
- 334 people
- Sponsor
- Eurofarma Laboratorios S.A.
Asthma
Bronchial Ablation for Treatment of Asthma (BATA) Trial
To evaluate the safety and efficacy of a bronchial radiofrequency ablation system (SyMap Medical (Suzhou) Ltd) in a population of subjects with severe asthma who are still symptomatic despite being managed on high-dose Inhaled…
- Trial name
- BATA (NCT03765307)
- Testing
- SyMap Bronchial Ablation System, Boston Scientific Alair System
- Where
- 15 sites in China
- Volunteers
- 160 people
- Sponsor
- SyMap Medical (Suzhou), Ltd.
Asthma, Bronchial
Study of Montelukast and Its Effect on Lower Leg Growth in Children With Asthma (MK-0476-254)
The purpose of this study is to determine the effect of montelukast, an approved medication, on the lower leg growth rate in children with mild asthma.
- Trial name
- NCT00092092
- Testing
- Montelukast chewable tablets, Budesonide inhaler
- Volunteers
- 71 people
- Sponsor
- Organon and Co
Asthma
A Study to Evaluate the Amount of Drug That Becomes Available to the Blood Circulation When Inhaled by a Nebulizer and Dry Powder Inhaler in Healthy Subjects.
The purpose of this study is to assess the relative bioavailability of the AZD7594 nebulized formulations (test) and the dry powder formulation (reference).
- Trial name
- NCT04072562
- Testing
- AZD7594
- Where
- Germany
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Persistent Asthma
A 12-week Safety and Efficacy Study of Beclomethasone Dipropionate (80 and 160 mcg/Day) Delivered Via Breath-Actuated Inhaler (BAI) in Patients >=12 Years Old With Persistent Asthma
This is a randomized, double-blind, placebo-controlled parallel-group study. Participants will be randomly assigned to receive treatment with beclomethasone dipropionate at a dosage of 80 or 160 mcg/day delivered via a…
- Trial name
- NCT02040779
- Testing
- Beclomethasone dipropionate breath-actuated inhaler, albuterol/salbutamol
- Where
- 47 sites in United States
- Volunteers
- 273 people
- Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
Asthma
Long-term Safety Study of QGE031 in Patients With Allergic Asthma Who Completed Study CQGE031B2201
This study planned to assess long-term safety of QGE031 during 12 months treatment in asthma patients who completed study CQGE031B2201.
- Trial name
- NCT02075008
- Testing
- QGE031
- Where
- 84 sites in United States, Argentina and 18 more
- Volunteers
- 270 people
- Sponsor
- Novartis Pharmaceuticals
Asthma
Omalizumab Use and Asthma-Related Quality of Life in Patients With Severe Persistent Allergic Asthma
This study investigated asthma-related quality of life in Brazilian patients using omalizumab.
- Trial name
- NCT00567476
- Testing
- Omalizumab, Inhaled corticosteroids (ICS), Long-acting beta 2-adrenergic agonist (LABA)
- Where
- Brazil
- Volunteers
- 116 people
- Sponsor
- Novartis
Allergic Rhinitis Due to Cat Allergy
A Study to Examine the Efficacy and Safety of Anti-Fel d 1 Antibodies Injections in Cat-allergic Adolescent and Adult Patients With Allergic Rhinitis Who Live With a Cat
The primary objective of the study is to determine the efficacy of REGN1908-1909, as compared to placebo, to reduce allergic rhinitis/conjunctivitis symptoms and allergy rescue medication use during natural cat exposure.
- Trial name
- NCT04981717
- Testing
- REGN1908-1909
- Where
- 92 sites in United States, Belgium and 4 more
- Volunteers
- 446 people
- Sponsor
- Regeneron Pharmaceuticals
Asthma
A Study of Lebrikizumab in Patients Whose Asthma is Uncontrolled With Inhaled Corticosteroids and A Second Controller Medication (LUTE)
This randomized, multicenter, double-blind, placebo-controlled, parallel-group study will assess the efficacy and safety of lebrikizumab in patients with asthma whose disease remains uncontrolled despite daily therapy with an…
- Trial name
- NCT01545440
- Testing
- lebrikizumab
- Where
- 71 sites in United States, Australia
- Volunteers
- 258 people
- Sponsor
- Genentech, Inc.
Asthma
A Study to Evaluate the Safety, Tolerability and Plasma Concentration Profiles of MK0633 in Asthmatic Children Aged 12 to Less Than 16 Years (0633-019)
To evaluate the safety, tolerability and pharmacokinetics (PK) of MK0633 in adolescent mild-to-moderate asthma patients to permit further clinical investigation.
- Trial name
- NCT00646789
- Testing
- Comparator: MK0633
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Asthma
A Study Of GSK679586A When Infused Into Healthy And Mild Asthmatic Volunteers
This is a two part study. Part I is designed to test single doses of GSK678586A in healthy volunteers. Part II is designed to test repeat doses (two doses) of GSK679586A in patients with mild asthma.
- Trial name
- NCT00411814
- Testing
- GSK679586
- Where
- 2 sites in Australia
- Volunteers
- 56 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Asthma
A Study to Investigate the Efficacy and Safety of GSK5784283 Compared With Placebo in Participants With Uncontrolled Asthma (PERSIST ASTHMA-1)
The study aims to demonstrate the superiority of GSK5784283 compared to placebo in reducing the annualized rate of clinically meaningful asthma exacerbations.
- Trial name
- NCT07780643
- Testing
- GSK5784283, Standard of care
- Where
- United States
- Volunteers
- 514 people
- Sponsor
- GlaxoSmithKline
Asthma
GB001 in Adult Subjects With Moderate to Severe Asthma
A randomized, double-blind, placebo-controlled, dose-ranging, multi-center study to evaluate the efficacy and safety of GB001 when added to standard-of care (SOC) asthma maintenance therapy in adults with moderate to severe…
- Trial name
- NCT03683576
- Testing
- GB001
- Where
- 117 sites in United States, Austria and 9 more
- Volunteers
- 481 people
- Sponsor
- GB001, Inc, a wholly owned subsidiary of Gossamer Bio, Inc.
Asthma
AMG 853 Phase 2 Study in Subjects With Inadequately Controlled Asthma
The primary objective is to determine if AMG 853 is effective compared with placebo as measured by change in Asthma Control Questionnaire (ACQ) composite symptoms scores from baseline to week 12.
- Trial name
- NCT01018550
- Testing
- AMG 853
- Volunteers
- 397 people
- Sponsor
- Amgen
Allergy to House Dust Mite, Allergic Asthma
Effects of Tregalizumab on Allergen-induced Airway Responses and Airway Inflammation in Asthmatic Patients
The study will be conducted as a randomized, double-blind, placebo-controlled, single-center study in adult patients with mild controlled allergic asthma and house dust mite allergy.
- Trial name
- Tregulaire (NCT04673591)
- Testing
- Tregalizumab
- Where
- Germany
- Volunteers
- 42 people
- Sponsor
- T-Balance Therapeutics GmbH
Asthma
FLOVENT Hydrofluoroalkane (HFA) In 6-12 Month Old Subjects
The purpose of this study is to address an Food Drug and Administration (FDA) request to provide safety data in pre-asthmatic patients, ages 6 months to <12 months, following administration of fluticasone propionate HFA.
- Trial name
- NCT00370097
- Testing
- FLOVENT (fluticasone propionate) HFA
- Where
- 7 sites in United States
- Volunteers
- 16 people
- Sponsor
- GlaxoSmithKline
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.